DUBLIN – (COMMERCIAL THREAD)–The “PCR Molecular Diagnostics Market – Growth, Trends, COVID-19 Impact, and Forecast (2021 – 2026)” report was added to ResearchAndMarkets.com offer.
The PCR molecular diagnostics market is expected to grow with an estimated CAGR of 3.5% during the forecast period.
PCRs are the most widely used diagnostic tests for detecting pathogens, including viruses. It is considered to be one of the best tests to identify the COVID 19 virus in the human body.
Growing technological advancements and growing public awareness of preventive care are propelling the growth of the market. Although COVID 19 is having a major impact on the medical industry, the PCR molecular diagnostics market is on a positive trend.
The increasing prevalence of cancer and infectious diseases is also a major factor driving the PCR molecular diagnostics market. The Infectious Diseases Society of America has said that every year there is a likelihood of new potentially dangerous bacteria, viruses and fungi such as Severe Acute Respiratory Syndrome (SARS).
The World Health Organization said in March 2020 that more than 17% of all infectious diseases are vector-borne. On top of that, World Cancer Facts and Figures, 4th Edition, released to the American Cancer Society, indicated that according to the International Agency for Research on Cancer (IARC), cancer cases are on the increase. and are expected to reach 27.5 million by 2040, aging is also a factor supporting the increase in new cancers.
The adoption and implementation of software related to molecular diagnostics in the respective diagnostic centers is expected to drive the market growth. In addition, molecular diagnosis by PCR has also played a crucial role in cancerous diseases. For example, in March 2020, a review conducted on diagnostic methods important to diagnosis and treatment related to cancer biomarkers indicated that polymerase chain reaction (PCR) and real-time PCR play a critical role in the development of cancer biomarkers. cancer diagnosis.
In addition, in June 2020, Mobidiag Ltd., announced that it had received CE-IVD markings for its Novodiag COVID-19 molecular diagnostic tests and Amplidiag COVID-19 for the early detection of the SARS-CoV-2 virus, responsible of the new coronavirus. infection (COVID-19).
Based on well-established high-throughput qualitative PCR technology, 48 samples can be processed in less than three hours while running on Mobidiag’s Amplidiag Easy platform. Hence, owing to the factors mentioned above, the market is expected to experience significant growth in the future.
The PCR molecular diagnostics market is moderately competitive with several players across the world. In terms of market share, few of the major players currently dominate the market. With the increasing levels of patient awareness and the high prevalence of infectious and cancerous diseases, especially COVID 19, many regional players are expected to increase their presence in the market.
Some of the major market players are Abbott Laboratories, Thermo Fisher Scientific, Inc., Bio-Rad Laboratories, Inc., Takara Bio, Inc., Qiagen NV
Main topics covered:
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market overview
4.2 Market drivers
4.2.1 Increased prevalence of cancer and infectious diseases
4.2.2 Technological advances in PCR devices
4.2.3 Growing Demand for Rapid Diagnostic Tests and Growing Adoption of PCR
4.3 Market restrictions
4.3.1 High cost of PCR instruments / devices
4.3.2 Strict regulatory policies
4.4 Porter’s five forces analysis
5 MARKET SEGMENTATION
5.1 By product
22.214.171.124 Standard PCR systems
126.96.36.199 Digital PCR systems
188.8.131.52 Real-time PCR systems
5.1.2 Reagents and consumables
5.2 By application
5.2.1 Screening for infectious diseases
5.2.2 Oncology tests
5.2.3 Other applications
5.3 By the end user
5.3.2 Diagnostic laboratories
6 COMPETITIVE LANDSCAPE
6.1 Company profiles
6.1.1 Abbott Laboratories
6.1.2 Thermo Fisher Scientific, Inc.
6.1.3 Bio-Rad Laboratories, Inc.
6.1.4 Takara Bio, Inc.
6.1.5 Qiagen SA
6.1.6 Danaher Company
6.1.7 Becton Dickinson and Company
6.1.8 Agilent Technologies, Inc.
6.1.9 Eppendorf AG
6.1.10 F. Hoffman-La Roche Ltée.
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
For more information on this report, visit https://www.researchandmarkets.com/r/swq6sd